Thymus Cancer - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Thymus Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Thymus Cancer - Pipeline Review, H2 2015', provides an overview of the Thymus Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thymus Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thymus Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thymus Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Thymus Cancer - Overview 7
Pipeline Products for Thymus Cancer - Comparative Analysis 8
Thymus Cancer - Therapeutics under Development by Companies 9
Thymus Cancer - Therapeutics under Investigation by Universities/Institutes 10
Thymus Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Thymus Cancer - Products under Development by Companies 12
Thymus Cancer - Products under Investigation by Universities/Institutes 13
Thymus Cancer - Companies Involved in Therapeutics Development 14
Cellceutix Corporation 14
Merck & Co., Inc. 15
Novartis AG 16
Onxeo SA 17
Sumitomo Dainippon Pharma Co., Ltd. 18
Tiziana Life Sciences Plc 19
Thymus Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
amrubicin hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
belinostat - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
buparlisib hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cellular Immunotherapy 2 for Oncology - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
KM-3174 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
milciclib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MK-2206 + selumetinib sulfate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pasireotide LAR - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pembrolizumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Thymus Cancer - Recent Pipeline Updates 59
Thymus Cancer - Product Development Milestones 91
Featured News & Press Releases 91
Aug 11, 2015: Cellceutixs Kevetrin and Thymoma - a Rare Cancer 91
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 91
May 14, 2014: Phase II data of Nerviano Medical Science's kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 92
Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas 92
May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables

Number of Products under Development for Thymus Cancer, H2 2015 7
Number of Products under Development for Thymus Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Thymus Cancer - Pipeline by Cellceutix Corporation, H2 2015 14
Thymus Cancer - Pipeline by Merck & Co., Inc., H2 2015 15
Thymus Cancer - Pipeline by Novartis AG, H2 2015 16
Thymus Cancer - Pipeline by Onxeo SA, H2 2015 17
Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 18
Thymus Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Assessment by Combination Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Thymus Cancer Therapeutics - Recent Pipeline Updates, H2 2015 59